Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It… Read more
Ryvu Therapeutics SA (RVU) - Total Assets
Latest total assets as of September 2025: zł255.34 Million PLN
Based on the latest financial reports, Ryvu Therapeutics SA (RVU) holds total assets worth zł255.34 Million PLN as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ryvu Therapeutics SA - Total Assets Trend (2010–2024)
This chart illustrates how Ryvu Therapeutics SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ryvu Therapeutics SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Ryvu Therapeutics SA's total assets of zł255.34 Million consist of 71.9% current assets and 28.1% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 42.3% |
| Accounts Receivable | zł20.92 Million | 5.5% |
| Inventory | zł1.21 Million | 0.3% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł8.12 Million | 2.1% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Ryvu Therapeutics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ryvu Therapeutics SA's current assets represent 71.9% of total assets in 2024, an increase from 24.9% in 2010.
- Cash Position: Cash and equivalents constituted 42.3% of total assets in 2024, up from 3.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 5.5% of total assets.
Ryvu Therapeutics SA Competitors by Total Assets
Key competitors of Ryvu Therapeutics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Ryvu Therapeutics SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ryvu Therapeutics SA generates 0.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ryvu Therapeutics SA is currently not profitable relative to its asset base.
Ryvu Therapeutics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.27 | 3.03 | 5.10 |
| Quick Ratio | 2.26 | 3.01 | 5.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł90.97 Million | zł 198.24 Million | zł 138.55 Million |
Ryvu Therapeutics SA - Advanced Valuation Insights
This section examines the relationship between Ryvu Therapeutics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.21 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -6.1% |
| Total Assets | zł378.78 Million |
| Market Capitalization | $100.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ryvu Therapeutics SA's assets below their book value (0.27 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ryvu Therapeutics SA's assets decreased by 6.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ryvu Therapeutics SA (2010–2024)
The table below shows the annual total assets of Ryvu Therapeutics SA from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł378.78 Million | -6.06% |
| 2023-12-31 | zł403.20 Million | -15.11% |
| 2022-12-31 | zł474.98 Million | +107.58% |
| 2021-12-31 | zł228.81 Million | -22.60% |
| 2020-12-31 | zł295.64 Million | +61.65% |
| 2019-12-31 | zł182.89 Million | -28.47% |
| 2018-12-31 | zł255.70 Million | +146.88% |
| 2017-12-31 | zł103.57 Million | +16.22% |
| 2016-12-31 | zł89.12 Million | +36.60% |
| 2015-12-31 | zł65.24 Million | +143.41% |
| 2014-12-31 | zł26.80 Million | +49.09% |
| 2013-12-31 | zł17.98 Million | +17.13% |
| 2012-12-31 | zł15.35 Million | -12.31% |
| 2011-12-31 | zł17.50 Million | +70.44% |
| 2010-12-31 | zł10.27 Million | -- |